Here’s Why Investors Should Ignore Elon Musk’s Latest AI Warning

Forget about North Korea.

Artificial intelligence, otherwise referred to as AI, is much more of a threat.

That is, according to SpaceX CEO Elon Musk.

“If you’re not concerned about AI safety, you should be,” Musk posted on his Twitter account on Aug. 11. “Vastly more risk than North Korea.”

elon muskThe business magnate’s latest warning came amid news that an AI system developed by OpenAI – a nonprofit co-founded by Musk – had defeated the best of the best players at a military strategy game, Dota 2.

The company was established to research and develop AI to help ensure that the technology is used for good. But now, Musk is getting worried...

In fact, this isn’t the first time Musk has warned of the “risks” of AI systems, like the one he uses in Tesla Inc.’s (Nasdaq: TSLA) self-driving car technology.

Earlier this year, he told Vanity Fair that even something as simple as strawberry-picking robots could end up taking over the world.

Yes, you read that right.

"Let's say you create a self-improving AI to pick strawberries," Musk said in the interview, "and it gets better and better at picking strawberries and picks more and more and it is self-improving, so all it really wants to do is pick strawberries. So then it would have all the world be strawberry fields. Strawberry fields forever."

Musk has long advocated for government regulation of the technology due to his close proximity to it.

"I have exposure to the very cutting-edge AI," he said on July 17 at a conference in Rhode Island, "and I think people should be really concerned about it."

We won’t argue whether or not robots will destroy the world in a misguided effort to complete the tasks assigned to them. But we do think Musk’s doomsday warnings are a distraction from the present-day implications of artificial intelligence:

AI can be extremely beneficial for not only investors, but also mankind.

Just look at what it’s doing with biotech...

How “Biointelligence” Could Save Countless Human Lives

Artificial intelligence isn’t just being used to make new drugs; it has the power to speed up the drug creation process itself. That means more effective treatment, faster, for everyone.

“AI harnesses the power of computing, machine learning, and advanced algorithms to greatly augment what human minds can do – and find profitable patterns they can't,” said Money Morning Director of Technology & Venture Capital Research Michael A. Robinson to readers on July 17.

BREAKING: New Legislation Could Turn Tiny Pot Stocks into Millions. Click Here…

Michael is our renowned biotechnology expert and one of our most prominent and respected investing "gurus" here at Money Morning – and for good reason.

He is one of the top financial analysts working today.

He's been a board member for a Silicon Valley venture capital firm and a senior advisor to 12 high-tech startups.

He's also a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style.

His research is world class, too. The Oakland Tribune, Detroit News, The San Francisco Examiner, The Kansas City Times, Wealth Magazine, and American Banker have all published his reporting. He's even appeared on Larry King's syndicated radio show and is a regular guest on CNBC's "The Rundown" and FOX Business Network's "Cavuto: Coast to Coast."

And Michael has discovered a tiny British company that is using its AI platform to discover small molecule treatments – and save lives – faster than ever before.

In fact, this company is doing it cheaper than anyone else.

“By combining two or more fields of tech – in this case biotech and AI – it's like a formula in which 1 + 1 = 3… and often a lot more that,” said Michael.

The company is called Exscientia Ltd. And it’s about to upend drug development as we know it.

“It now takes roughly five years from the time scientists begin looking at an area of disease before they land on a promising compound,” Michael said. “Then after that, a drug firm will spend an average of $2.9 billion over the course of 10 years to get the resulting treatment through U.S. Food and Drug Administration approval and out to patients.”

Now, Exscentia is changing all of that by using AI.

The firm’s biointelligence engine combs through studies to find the best practices, then employs Big Data to sift through millions of project-specific compounds, and finally produces a list of data-rich compounds ripe for testing in the lab.

Put simply, AI allows the company to scan large amounts of data faster than any human can to produce the best possible solutions in one try.

“With this biointelligence process, Exscientia says it can come up with a list of promising compounds in one-fourth the time of standard approaches,” said Michael. “That's huge – both for patients looking for more effective treatments and for investors looking for bigger gains.”

And while Exscientia Ltd. isn’t yet a publicly traded company, Michael has found a way for investors to get in on the action.

In fact, he’s found two ways. And both of them will lead you to outsized returns – and hefty dividends.

Read more about Michael’s newest “biointelligence” play, right here…

Editor’s Note: One of the fastest-growing tech investment segments is… cannabis? Yes, you read that right. A high-tech approach to cultivating this ancient plant – that's already legal to use in more than half of 50 states – is generating a multibillion-dollar investment opportunity for early investors. Click here to find out more, including how you can get your copy of Michael Robinson's Roadmap to Marijuana Millions. Packed with more than 30 great companies to buy, it's fast becoming "the weed investor's bible." Check it out…

Follow Money Morning on Twitter @moneymorningFacebook, and LinkedIn.

[mmpazkzone name="end-story-hostage" network="9794" site="307044" id="138536" type="4"]